⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1765361 | 0.81 | — | — | |
| SCHEMBL1923395 | 0.71 | — | — | |
| SCHEMBL4580892 | 0.69 | TDP1 (0.39) | — | |
| SCHEMBL1615049 | 0.69 | TSHR (0.39) | — | |
| SCHEMBL1025861 | 0.66 | TSHR (0.36) | — | |
| SCHEMBL20526404 | 0.66 | TDP1 (0.36) | — | |
| SCHEMBL3291304 | 0.66 | TDP1 (0.36) | — | |
| SCHEMBL20509901 | 0.66 | TDP1 (0.36) | — | |
| SCHEMBL1021983 | 0.66 | TSHR (0.36) | — | |
| SCHEMBL1021515 | 0.66 | TSHR (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116063281-B | Compound as ligand-gated ion channel receptor modulator, and preparation and application thereof | 中国科学技术大学 | 2023-11-21 | — | — | CN | claimed |
| CN-116063281-A | Compound as ligand-gated ion channel receptor modulator, and preparation and application thereof | 中国科学技术大学 | 2023-05-05 | — | — | CN | claimed |
| CN-116063281-B | Compound as ligand-gated ion channel receptor modulator, and preparation and application thereof | 中国科学技术大学 | 2023-11-21 | — | — | CN | disclosed |
| CN-116063281-A | Compound as ligand-gated ion channel receptor modulator, and preparation and application thereof | 中国科学技术大学 | 2023-05-05 | — | — | CN | disclosed |
| US-8609892-B2 | Glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2013-12-17 | — | — | US | disclosed |
| US-20110124648-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100324140-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2010-12-23 | — | — | US | disclosed |
| US-7816557-B2 | 3-{4-[1-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]-benzoylamino}-propionic acid; treat diabetic and other glucagon related metabolic disorders | ELI LILLY AND COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| EP-2159221-A1 | Glucagon receptor antagonists, preparation and therapeutic uses | Eli Lilly & Company (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-1758853-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20070249688-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1758853-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123668-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |
| US-4154756-A | HYPOLIPIDEMIC AND ANTIATHEROSCLEROTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1979-05-15 | — | — | US | disclosed |